Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction

World Journal of Urology

Volumn 19, Issue 1, 2001, Pages 14-22

  Ückert, Stefan ^a   Küthe, Andrea ^a   Stief, Christian G ^a   Jonas, Udo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ISOENZYME; PHOSPHODIESTERASE;

DRUG EFFECT; ENZYMOLOGY; HUMAN; IMPOTENCE; MALE; PENIS; PHYSIOLOGY; REVIEW;

CYCLIC GMP; HUMANS; IMPOTENCE; ISOENZYMES; MALE; PENIS; PHOSPHORIC DIESTER HYDROLASES;

EID: 0035257809     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007090     Document Type: Article

References (49)

1. Andersson K-E, Wagner G (1995) Physiology of penile erection. Phamacol Rev 75: 191-236
2. Andersson K-E. Holmquist F (1994) Regulation of tone in penile cavernous smooth muscle. Established concepts and new findings. World J Urol 12: 249-261
3. Mandrek K. (1994) Electrophysiological methods in smooth muscle physiology. Corpus cavernosum in vitro. World J Urol 12: 262 265
4. Mersdorf A. Goldsmith PC, Diederichs W (1991) Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J Urol 145: 749-758
5. Holmquist F, Hedlund H, Andersson K-E (1991) NG-Nitro-Larginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol Scand 141: 441-442
6. Holmquist F, Stief CG, Jonas U, Andersson K-E (1991) Effects of the nitric oxide synthase inhibitor NG-nitro-L-arginine on the erectile response to cavernous nerve stimulation in the rabbit. Acta Physio! Scand 143: 299-304
7. Ignarro LJ, Bush PA, Buga GM, Woods KS, Fukuto JM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Comm 170: 843 850
8. Truss MC, Becker AJ, Schultheiss D, Jonas U (1997) Intracavernous pharmacotherapy. World J Urol 15: 71-77
9. Truss MC. Becker AJ, Djamillian MH, Stief CG, Jonas U (1994) Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 44: 553 556
10. Gingell CJC, Jardin A. Olsson AM, Dinsmore WW, Osterloh I A. Kirkpatrick M (1996) UK-92.480, a new oral treatment for erectile dysfunction: a double-blind, placebo-controlled, once daily dose response study. J Urol 155 [Suppl]: 495A
11. Patma-Nathan H. McMurray J. Saoud J, Ferguson K, Dullman W, Whitaker S, Rosen R (2000) On-demand treatment of erectile dysfunction with 1C 351. Eur Urol 37 [Suppl 2]: 80
12. Sachse R, Rohde G (2000) Safety, tolerability and pharmacokinetics of multiple dose treatment with the new PDE5 inhibitor BAY 38-9456. Eur Urol 37 [Suppl 2]: 81
13. Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U (1998) The effects of the specific phosphodiesterase 4 inhibitor rolipram on the uretral peristalsis of the rabbit in vitro and in vivo. J Urol 160: 920 925
14. Truss MC. Stief CG, Ückert S. Becker AJ, Forssmann WG, Jonas U (1997) Initial clinical experience with the selective phosphodiesterase (PDE) 1 isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. J Urol 157 [Suppl]: 187
15. Seemann C, Ückert S, Stief CG. Bischoff E, Schramm M, Jonas U (1999) Relaxation of human detrusor smooth muscle in vitro by modulation of cyclic nucleotide dependent pathways. Eur Urol 35 [Suppl 2]: 93
16. Stief CG, Ückert S, Truss MC, Jonas U (2000) Initial characterization of phosphodiesterase isoenzymes from human prostatic tissue. Eur Urol 37 [Suppl 2]: 76
17. Heaton JP, Morales A, Owen J (1990) Topical glyceryltrinitrate causes measurable penile arterial dilatation in impotent men. J Uroi 143:729-731
18. Porst H (1996) The rationale for prostaglandin EI in erectile failure: a survey of worldwide experience. J Urol 155: 802-815
19. Ottensen B, Wagner G, Virag R, Fahrenkrug J (1984) Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter. Br J Med 288: 9-11
20. Cahn D, Melman A, Valcic M, Christ GJ (1997) Forskolin: a promising new adjunct to intracavernous pharmacotherapy. .1 Urol 155: 1789-1794
21. Nehra A, Barret DM, Moreland RB (1999) Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo ClinProc74: 709-721
22. Lue TF, Dahiya R (1997) Molecular biology of erectile function and dysfunction. Mol Urol 1: 55 64
23. Thompson WJ (1991) Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 51: 13-33
24. Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sei 12: 19-27
25. Hall IP (1993) Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmacol 35: 1-7
26. Michaeli T, Bloom TJ, Martins T. Loughney K. Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M (1994) Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase deficient Saccharomyces cerevisiae. J Biol Chem 268: 191: 12925-12932
27. Fisher AD, Smith JF, Pillar JS, St. Denis S, Cheng JB (1998) Isolation and characterization of PDE8A, a novel cAMPspecific phosphodiesterase. Biochem Biophys Res Commun 246: 570-577
28. Fisher AD, Smith JF, Pillar JS, St. Denis S, Cheng JB (1998) Isolation and characterization of PDE9A, a novel cGMPspecific phosphodiesterase. J Biol Chem 273: 15559-15564
29. Loughney K, Snyder PB, Uher L, Rosman GJ, Ferguson K, Florio VA (1999) Isolation and characterization of PDE10A, a novel human 3'.5'-cyclic nucleotide phosphodiesterase. Gene 234: 109-117
30. Fawcett L. Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Philips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sei USA 97: 3702-3707
31. Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63: 1-38
32. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12: 174-179
33. Küthe A. Wiedenroth A, Stief CG, Magert HJ, Ückert S. Forssmann WG, Jonas U (1999) Identification of 13 phosphodiesterase isoforms in human cavernous tissue. Eur Urol 35 [Suppl2]: 101
34. Taher A, Stief CG, Raida M, Jonas U, Forssmann WG (1992) Cyclic nucleotide phosphodiesterase activity in human cavernous smooth muscle and the effect of various selective inhibitors. Int J Impôt Res 4 [Suppl 2]: 11
35. Boolell M, Alien MJ, Ballard S, Gepi-Attee S, Muirhead GJ, Naylor AM. Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cGMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impôt Res 8: 47 52
36. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159: 2164 2171
37. Stief CG, Ückert S, Becker AJ. Truss MC, Jonas U (1998) EfTects of specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J LJrol 159: 1390-1393
38. Moreland RB. Goldstein I, Kim NN, Traish A (1999) Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol Metab 10: 97-104
39. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397-1404
40. Kiithe A, Magert HJ, Ückert S, Forssmann WG, Stief CG, Jonas U (2000) Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. Eur Urol 38: 108-114
41. Rulten SL, Dapling JL, Lanfa SC, Steel J. Turay P. Paulson R (1998) Isolation of human phosphodiesterase 5 cDNA and in situ analysis of its expression in human corpus cavernosum. J Urol 159: 92A
42. Beavo JA, Reifsnyder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. TIPS 11: 150-155
43. Stief CG, Ückert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, Jonas U (2000) Effects of Sildenafil on cAMP
44. and cGMP levels in isolated human cavernous and cardiactissue. Urology 55: 146 150
45. Jeremy JY, Ballard SA. Naylor AM, Miller MA. Angelini GD (1997) Effects of sildenafil, a type 5 cGMP phosphodieslerase inhibitor, and papaverine on cyclic GMP and cyclic AMI' levels in the rabbit corpus cavernosum. Br J Urol 79: 958 963
46. Chuang AT, Strauss JD, Murphy RA, Steers WD (1998) Sildenafil. a type 5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 160: 257 261
47. Andersson K-E, Stief CG (2000) Penile erection and cardiac risk: pathophysiologic and pharmacologie mechanisms. Am .1 Cardiol 86 [Suppl]: 23F-26F
48. Maurice DH, Haslam RJ (1990) Nitroprusside enhances isoprenaline-induced increases in cAMP in rat aortic smooth muscle. Eur J Pharmacol 191: 471175
49. Jiang H, Colbran JL, Francis SH, Corbin JD (1992) Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. J Biol Chem 267: 1015-1019